查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916882

康恩氏症候群治疗市场按药物类别、治疗线、给药途径和分销管道划分－全球预测（2026-2032 年）

Drugs for Conn's Syndrome Market by Drug Class, Therapy Line, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 Conn 症候群治疗市场价值为 2.3432 亿美元，预计到 2026 年将成长至 2.5839 亿美元，预计到 2032 年将达到 4.6754 亿美元，复合年增长率为 10.37%。

主要市场统计数据
基准年 2025 2.3432亿美元
预计年份：2026年 2.5839亿美元
预测年份：2032年 4.6754亿美元
复合年增长率 (%) 10.37%

全面介绍目前治疗方案、临床挑战和研究重点，这些因素共同影响康恩氏症候群（正式名称为原发性醛固酮增多症）的医疗管理。

本文全面概述了康恩氏症候群（原发性醛固酮增多症）的治疗现状，包括临床背景、治疗原理以及临床医生和医疗保健系统需要关注的关键决策点。原发性醛固酮增多症的特征是醛固酮分泌过多，需要考虑多种治疗策略，包括盐皮质激素受体拮抗剂治疗、选择性手术干预以及心血管和肾臟后遗症的长期监测。鑑于症状的异质性和可用药物的种类繁多，临床医生在选择治疗方案时必须权衡疗效、耐受性和合併症的控制。

药物研发、法规结构和临床实践的变革性变化正在重新定义原发性醛固酮增多症的治疗途径。

本节检验了正在重塑药物研发、法规环境和临床实践的变革性变化，并着重于高醛固酮症患者治疗途径的动态。近期趋势包括：重新关注能够提高耐受性并维持或增强疗效的机制特异性药物；以及监管机构更加重视在合併多种疾病的人群中进行全面的安全性评估。这些变化正在改变药物研发的时间表，并要求申办者收集更全面的安全性和疗效资料集。

提案的美国关税在2025年对供应链、製造成本和康纳斯综合征患者治疗获取的累积影响

本分析检验了2025年预计生效的美国关税对康恩氏症候群治疗药物生产、采购和分销系统的累积影响。关税的征收或调整将影响原料药、中间体和成品进口的根本经济效益，并对下游流程（例如生产计画、库存策略和供应商选择）产生连锁反应。製造地地域集中的企业更容易受到贸易政策波动的影响，这可能表现为前置作业时间延长、单位成本上升以及需要多元化供应商网路。

深入了解不同药物类别、治疗线、给药途径和分销管道的患者细分和治疗标靶

本节透过深入的細項分析，阐明如何根据产品和患者群体特征调整临床和商业策略。按药物类别划分，我们将重点放在非类固醇盐皮质激素受体拮抗剂 (NMA) 和类固醇类盐皮质激素受体拮抗剂 (SMA)。前者以Finerenone为临床代表，后者则包括依普利酮和Spiranolactone等已上市药物。理解这些差异至关重要，因为 NMA 通常以增强选择性和耐受性为卖点，而甾体类药物则具有已知的常规特性和广泛的脱靶效应，这些都会影响药物的配製行为。

影响醛固酮相关疾病临床应用、支付方决策和就医管道的区域趋势和医疗保健系统驱动因素

区域动态对美洲、欧洲、中东和非洲以及亚太地区的临床应用、报销管道和营运执行有着至关重要的影响。每个地区的医疗保健系统结构和相关人员的期望各不相同。在美洲，支付方主导的趋势和大规模综合医疗网络强调价值证明和以结果为导向的合同，鼓励製造商投资于真实世界证据和患者支持项目。相较之下，欧洲、中东和非洲的报销模式多种多样，一些地区优先考虑卫生技术评估和成本效益分析，而另一些地区则专注于透过协商定价和管理式入门合约来提高药物可及性。

影响盐皮质激素受体拮抗剂开发和商业化策略的策略性企业行动、合作模式和竞争定位

此治疗领域的公司层面趋势反映了现有企业、非类固醇类盐皮质激素受体拮抗剂创新者、契约製造以及专注于差异化药理学和新型给药方式的新兴生物技术公司的多元化格局。Spiranolactone和依普利酮等成熟药物继续由多家非专利生产商供应，这支持了其广泛的临床认可，但也给许多市场的价格和利润率带来了压力。同时，非类固醇类替代药物基于耐受性和目标受体相互作用，引入了独特的竞争维度，促使药物研发者投资于更广泛的适应症，并建立在合併多种疾病的各类患者群体中的疗效证据。

为行业领导者提供切实可行的优先建议，以加速临床影响、增强供应链韧性并推进以患者为中心的护理

这些切实可行的建议优先考虑行业领导者可以采取的实际步骤，以加速临床应用、增强供应链韧性并提升整个治疗管道中以患者为中心的护理水平。首先，各机构应使其临床开发项目与支付方相关的终点指标保持一致，并纳入患者报告结果，以增强其在处方笺讨论和价格谈判中的价值主张。其次，供应链和采购负责人应实施多源采购策略，并对关键中间体的替代供应商进行资格认证，以降低贸易政策变更和物流中断的风险。

一份详尽的调查方法概述，描述了支撑治疗模式和结果分析的资料来源、相关人员参与和分析方法。

该调查方法概述了一种整合临床、监管和营运资讯的综合方法，强调资料来源的透明度、相关人员的参与以及分析方法的严谨性。分析整合了同行评审的临床文献、监管文件、实验室註册资讯和药物监测摘要，以建立关于药物有效性、安全性和使用模式的可靠证据基础。此外，透过对临床医生、支付方顾问、供应链经理和临床营运负责人进行结构化访谈，进行了初步研究，从而对趋势进行了背景解读，并检验了新出现的假设。

简明扼要的结论整合了临床、监管、供应链和以患者为中心的主题，为整个医疗保健系统的相关人员概述了下一步行动。

结论总结了报告的关键主题：新型选择性更强的盐皮质激素受体拮抗剂的临床应用前景；需要更有力的真实世界证据来满足支付方的期望；供应链和贸易政策趋势对运营的影响；以及需要製定本地化的准入策略。在这些主题中，临床证据与卫生系统优先事项之间的相互作用凸显为治疗药物的采纳和患者可及性的核心决定因素。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8.康恩氏症候群治疗市场（依药物类别划分）

  • 非类固醇盐皮质激素受体拮抗剂
  • 类固醇类盐皮质激素受体拮抗剂
    • 依普立酮
    • Spiranolactone

9. 康恩氏症候群药物市场（依治疗系列划分）

  • 主要治疗
  • 二级治疗
  • 三级或以上治疗

10.康恩氏症候群治疗市场依给药途径划分

  • 静脉注射
  • 口服

第十一章 康恩氏症候群治疗市场（依分销管道划分）

  • 医院药房
  • 零售药房

12. 各地区康恩氏症候群治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 康恩氏症候群治疗市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国康恩氏症候群治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国康恩氏症候群治疗市场

第十七章：中国的康恩氏症候群治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-AE420CB153CD

The Drugs for Conn's Syndrome Market was valued at USD 234.32 million in 2025 and is projected to grow to USD 258.39 million in 2026, with a CAGR of 10.37%, reaching USD 467.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 234.32 million
Estimated Year [2026] USD 258.39 million
Forecast Year [2032] USD 467.54 million
CAGR (%) 10.37%

Comprehensive introduction to current therapeutic options, clinical challenges, and research priorities shaping medical management of Conn's syndrome

The introduction frames the therapeutic landscape for Conn's syndrome, formally known as primary aldosteronism, by synthesizing clinical context, treatment rationale, and key decision points for clinicians and healthcare systems. Primary aldosteronism presents with excess aldosterone production, which drives treatment considerations around mineralocorticoid receptor antagonism, surgical intervention in selected cases, and long-term monitoring for cardiovascular and renal sequelae. Given the heterogeneity of presentation and the range of available pharmacologic agents, clinicians must balance efficacy, tolerability, and comorbidity management when selecting therapy.

This section highlights the clinical imperatives that drive product and program priorities. Diagnostic advances and increased screening awareness have sharpened the clinical conversation around earlier identification and targeted treatment, while evolving safety and tolerability profiles of competing agents inform positioning strategies. In parallel, payers and health systems are increasingly focused on real-world outcomes and value-based measures, which reshape formulary and access dialogues.

Consequently, therapeutic strategy now requires coordinated planning across development, regulatory, and commercial functions. Clinical development teams must integrate head-to-head tolerability and adherence evidence into protocols, regulatory affairs professionals need to align label claims with outcome measures, and commercial leaders must craft access narratives that resonate with payers and prescribers. This introduction sets the scene for deeper analysis of the transformative shifts, supply chain pressures, segmentation nuances, regional dynamics, corporate behaviors, and pragmatic recommendations that follow.

Transformative shifts in drug development, regulatory frameworks, and clinical practice that are redefining therapeutic pathways for primary aldosteronism

This section examines the transformative shifts reshaping drug development, regulatory conditioning, and clinical practice, with a focus on how those dynamics are redefining therapeutic pathways for patients with aldosterone excess. Recent shifts include a renewed emphasis on mechanism-specific agents that aim to improve tolerability while preserving or enhancing efficacy, and a stronger regulatory preference for robust safety characterization in diverse, comorbid populations. These changes have altered development timelines and have required sponsors to build more comprehensive safety and outcomes datasets.

Clinical practice has responded in kind, with heightened screening and diagnosis driving earlier therapeutic intervention and more nuanced treatment algorithms. The interaction between clinical evidence generation and payer expectations has become more iterative, prompting manufacturers to generate real-world evidence and to align trial endpoints with payer-relevant outcomes. Additionally, advances in pharmacology-particularly next-generation mineralocorticoid receptor antagonists-are shifting prescriber preference toward agents that offer improved selectivity and reduced off-target effects, thereby influencing adoption patterns in specialty clinics and primary care.

Operationally, development stakeholders are adopting adaptive and pragmatic trial designs, real-world evidence strategies, and more proactive pharmacovigilance programs to de-risk approvals and reimbursement discussions. As a result, research prioritization, regulatory engagement, and market-entry strategies now require integrated planning across clinical, regulatory, and commercial disciplines to ensure new therapies can meet the simultaneously rising bar for clinical meaningfulness and system-level value.

Cumulative impacts of proposed United States tariff policies in 2025 on supply chains, manufacturing costs, and patient access to Conn's syndrome therapies

This analysis explores the cumulative implications of anticipated United States tariff measures in 2025 on manufacturing, procurement, and distribution systems that underpin access to therapies used in Conn's syndrome. The imposition or adjustment of tariffs affects the underlying economics of active pharmaceutical ingredient sourcing, intermediate materials, and finished product imports, with downstream consequences for production planning, inventory strategies, and supplier selection. Companies with geographically concentrated manufacturing footprints face higher exposure to trade policy volatility, which can manifest as extended lead times, increased unit costs, and the need to diversify supplier networks.

Regulatory and procurement teams must therefore reassess supplier contracts and qualification pathways to mitigate the impact of cost inflation on product availability and patient access. Parallel to procurement responses, manufacturers are likely to accelerate nearshoring and dual-sourcing strategies where feasible, and to renegotiate terms with contract manufacturers and logistics providers to maintain continuity of supply. Payers and hospital systems may in turn adjust procurement behaviors and formulary management to manage budgetary pressures, placing a premium on cost-effectiveness data and total cost of care analyses.

Clinicians and patient advocacy groups may experience indirect impacts through access restrictions or prior authorization practices if cost pressures intensify. Consequently, transparency in supply chain decision-making, proactive stakeholder communication, and scenario-based contingency planning will be essential to maintain therapeutic continuity and to safeguard patient outcomes in the face of shifting trade policies.

Deep insights into patient segmentation and therapeutic targeting across drug classes, therapy lines, routes of administration, and distribution channels

This section provides deep segmentation-derived insights that clarify how clinical and commercial strategies should be tailored to distinct product and patient groupings. By drug class, attention centers on nonsteroidal mineralocorticoid receptor antagonists and steroidal mineralocorticoid receptor antagonists, recognizing that the former is exemplified clinically by finerenone, while the latter category includes established agents such as eplerenone and spironolactone. Understanding these distinctions is essential because nonsteroidal agents are frequently positioned around improved selectivity and tolerability, whereas steroidal agents carry recognized legacy profiles and broad off-target effects that inform prescribing behavior.

Across therapy lines, segmentation into first line therapy, second line therapy, and third or later therapy reveals the strategic imperatives for evidence generation and messaging. First line positioning requires strong tolerability and adherence data, second line use often centers on comparative effectiveness versus established agents, and third or later therapy narratives must emphasize safety in polypharmacy contexts. By route of administration, differentiation between intravenous administration and oral administration affects inpatient versus outpatient utilization patterns, with oral agents commanding daily adherence considerations and intravenous options supporting acute management scenarios.

Distribution channel segmentation differentiates hospital pharmacy and retail pharmacy dynamics, which in turn shape contracting approaches, stocking practices, and patient counseling touchpoints. Hospital pharmacies often focus on formularies, inpatient protocols, and acute dosing logistics, whereas retail pharmacies influence outpatient access, prescription refill patterns, and patient education. Synthesizing these segmented dimensions enables sponsors and providers to align clinical evidence, access strategies, and operational execution to the distinct needs of each subgroup.

Regional dynamics and healthcare system drivers shaping clinical adoption, payer decisions, and access pathways across regions for aldosterone disorders

Regional dynamics exert a decisive influence on clinical adoption, reimbursement pathways, and operational execution across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct healthcare system architectures and stakeholder expectations. In the Americas, payer-driven dynamics and large integrated delivery networks emphasize value demonstration and outcome-oriented contracting, prompting manufacturers to invest in real-world evidence and patient support programs. In contrast, Europe, the Middle East & Africa encompasses heterogeneous reimbursement models; some jurisdictions prioritize health technology assessment and cost-effectiveness analysis, while others focus on access through negotiated pricing and managed entry agreements.

Within Asia-Pacific, diverse regulatory pathways and rapidly evolving private and public payer structures produce a mixture of opportunities and constraints. Rapid regulatory modernization in select markets accelerates approval timelines for novel agents, but fragmented distribution systems and variable reimbursement policies require tailored commercial and access plans. Across these regions, supply chain design, clinical trial site selection, and post-marketing surveillance must be adapted to local regulatory nuance and healthcare delivery modalities.

Consequently, multinational strategies should combine centralized evidence generation with region-specific access and commercialization plans. This hybrid approach allows for consistent clinical positioning while enabling local teams to address payer expectations, clinician preferences, and logistical constraints. Cross-regional collaboration between medical affairs, market access, and supply chain leads is therefore essential to translate clinical innovation into widespread, equitable patient benefit.

Strategic corporate behaviors, collaboration models, and competitive positioning influencing development and commercialization strategies for mineralocorticoid receptor antagonists

Company-level dynamics in this therapeutic area reflect a mix of legacy manufacturers, innovators of nonsteroidal mineralocorticoid receptor antagonists, contract manufacturing organizations, and emerging specialty biotech players focused on differentiated pharmacology and novel delivery modalities. Established agents such as spironolactone and eplerenone continue to be supplied by multiple generic manufacturers, which supports broad clinical familiarity but also compresses price and margins in many markets. Meanwhile, nonsteroidal alternatives have introduced a distinct competitive axis based on tolerability and targeted receptor interactions, prompting originator companies to invest in expanded label claims and broader evidence of benefit across comorbid populations.

Strategic behaviors include licensing arrangements to expand geographic reach, manufacturing partnerships to de-risk supply continuity, and targeted alliances to generate real-world evidence that supports payer engagement. Companies with robust global manufacturing footprints and diversified supplier networks gain operational resilience, while those with specialized clinical development capabilities can accelerate differentiated positioning. Additionally, service providers such as contract research organizations and pharmacovigilance partners play a critical role in supporting complex trial designs and safety monitoring that underpin regulatory submissions and post-approval commitments.

Overall, the competitive environment is characterized by pragmatic collaboration, portfolio diversification, and an emphasis on evidence generation that speaks both to prescribers and payers. These company-level strategies determine who can most effectively translate scientific advantage into durable clinical adoption and sustainable commercial performance.

Practical prioritized recommendations for industry leaders to accelerate clinical impact, strengthen supply resilience, and advance patient centricity in care

Actionable recommendations prioritize practical steps industry leaders can take to accelerate clinical impact, reinforce supply resilience, and elevate patient-centered care across treatment pathways. First, organizations should align clinical development programs with payer-relevant endpoints and incorporate patient-reported outcomes to strengthen the value narrative for formulary discussions and price negotiations. Second, supply chain and procurement leaders should implement multi-sourcing approaches and qualify alternative suppliers for key intermediates to reduce exposure to trade policy shifts and logistical disruption.

Third, commercialization teams must invest in targeted education for prescribers that clarifies the comparative tolerability, safety monitoring, and adherence implications of different classes and agents, thereby facilitating appropriate therapy selection. Fourth, payers and manufacturers should collaborate on outcomes-based contracting pilots where feasible, using real-world evidence to link payment to measurable clinical benefits and to mitigate budgetary uncertainty. Fifth, medical affairs functions should prioritize post-market evidence generation, including registry data and pragmatic studies, to sustain a stream of clinically relevant insights that address real-world utilization patterns.

Finally, patient support services that focus on adherence, side-effect management, and streamlined access pathways will materially influence long-term treatment success. By operationalizing these recommendations, organizations can convert analytic insight into tangible improvements in clinical outcomes, access equity, and commercial durability.

Robust research methodology overview describing data sources, stakeholder engagement, and analytic techniques underpinning treatment patterns and outcomes analysis

The research methodology outlines the integrated approach used to compile clinical, regulatory, and operational insights, emphasizing transparency in data sources, stakeholder engagement, and analytic methods. The analysis synthesized peer-reviewed clinical literature, regulatory documents, clinical trial registries, and pharmacovigilance summaries to construct a robust evidence base on efficacy, safety, and utilization patterns. In addition, primary research via structured interviews with clinicians, payer advisors, supply chain managers, and clinical operations leaders provided contextual interpretation of trends and validated emergent hypotheses.

Analytic techniques combined qualitative thematic synthesis with structured evidence-mapping to align trial endpoints and safety signals with real-world utilization pathways. Quality assurance included cross-validation of primary interview findings with publicly available regulatory summaries and clinical guidelines, plus iterative expert review to ensure interpretive accuracy. Limitations are acknowledged: evolving trial results and regulatory decisions may shift the evidence base, and regional heterogeneity can temper the generalizability of certain operational recommendations. To mitigate these constraints, the methodology incorporated scenario analysis and sensitivity checks to test the robustness of strategic implications.

Taken together, this mixed-methods approach balances depth and breadth, producing actionable insights that reflect both empirical evidence and practitioner experience. The methodology supports reproducibility and provides a clear audit trail for the assumptions underlying the report's conclusions and recommendations.

Concise conclusion synthesizing clinical, regulatory, supply chain, and patient-centred themes to inform next steps for stakeholders across healthcare systems

The conclusion synthesizes the report's principal themes: the clinical promise of newer, more selective mineralocorticoid receptor antagonists; the need for stronger real-world evidence to satisfy payer expectations; the operational implications of supply chain and trade policy dynamics; and the necessity of regionally adapted access strategies. Across these themes, the interaction between clinical evidence and health system priorities emerges as the central determinant of therapeutic adoption and patient access.

Looking forward, successful programs will be those that integrate evidence generation with pragmatic access planning, resilient supply chain design, and stakeholder-aligned commercialization strategies. Clinical differentiation must be supported by tangible data on tolerability and adherence in routine care, and by clear communication that translates those findings into prescriber and payer value propositions. Operationally, manufacturers should pre-emptively address potential supply disruptions and cost pressures through diversified sourcing and contingency planning.

Ultimately, the path from clinical innovation to sustained patient impact requires coordinated execution across development, regulatory, commercial, and operational functions. Stakeholders who align these disciplines and who invest in the evidence and infrastructure that matter to clinicians and payers will be best positioned to deliver meaningful improvements in care for patients with aldosterone-driven hypertension.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for Conn's Syndrome Market, by Drug Class

  • 8.1. Nonsteroidal Mineralocorticoid Receptor Antagonists
  • 8.2. Steroidal Mineralocorticoid Receptor Antagonists
    • 8.2.1. Eplerenone
    • 8.2.2. Spironolactone

9. Drugs for Conn's Syndrome Market, by Therapy Line

  • 9.1. First Line Therapy
  • 9.2. Second Line Therapy
  • 9.3. Third Or Later Therapy

10. Drugs for Conn's Syndrome Market, by Route Of Administration

  • 10.1. Intravenous Administration
  • 10.2. Oral Administration

11. Drugs for Conn's Syndrome Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Retail Pharmacy

12. Drugs for Conn's Syndrome Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drugs for Conn's Syndrome Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drugs for Conn's Syndrome Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Drugs for Conn's Syndrome Market

16. China Drugs for Conn's Syndrome Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aurobindo Pharma Limited
  • 17.6. Cipla Limited
  • 17.7. Dr. Reddy's Laboratories Limited
  • 17.8. Glenmark Pharmaceuticals Limited
  • 17.9. Lupin Limited
  • 17.10. Pfizer Inc.
  • 17.11. Sandoz International GmbH
  • 17.12. Sun Pharmaceutical Industries Ltd.
  • 17.13. Teva Pharmaceutical Industries Ltd.
  • 17.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY EPLERENONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY EPLERENONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY EPLERENONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SPIRONOLACTONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SPIRONOLACTONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY FIRST LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY FIRST LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY FIRST LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SECOND LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SECOND LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SECOND LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THIRD OR LATER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THIRD OR LATER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THIRD OR LATER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GCC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GCC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. GCC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 99. GCC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 100. GCC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. GCC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. G7 DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. G7 DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. G7 DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 117. G7 DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 118. G7 DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. G7 DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. NATO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NATO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. NATO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 123. NATO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 124. NATO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. NATO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)